- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Expanding the Therapeutic Horizon in MASH
Panelists discuss how next-generation metabolic and hepatic agents are broadening treatment options and reshaping the MASH care landscape.
EP: 1.Understanding the Metabolic–Hepatic Connection in MASH
EP: 2.Enhancing Early Detection and Diagnosis in MASH
EP: 3.Recognizing Risk and the Broader Health Impact in MASH
EP: 4.Evidence for GLP-1 Therapy in MASH
EP: 5.Expanding the Therapeutic Horizon in MASH
EP: 6.Balancing Clinical and Economic Considerations in Treatment Adoption
Panelists discuss how the therapeutic landscape for MASH is rapidly diversifying beyond GLP-1 receptor agonists. They explore the potential of dual-acting GLP-1/glucagon agents, thyroid hormone receptor (THR-β) agonists, and other novel compounds currently in advanced trials.
They describe how these emerging therapies aim to target multiple metabolic pathways simultaneously—reducing hepatic fat, improving fibrosis, and addressing systemic inflammation. The group underscores the excitement surrounding recent phase 2 and phase 3 results that suggest meaningful disease modification.
Finally, panelists discuss how the approval of these agents will influence payer decisions, formulary design, and access strategy, ensuring innovation is balanced with affordability.
